Clinical Trial Update: Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate the potential effect of apalutamide on EGFR expression in non-muscle invasive bladder cancer; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING